Pittenger & Anderson Inc. Cuts Stake in Zoetis Inc. $ZTS

Pittenger & Anderson Inc. decreased its holdings in Zoetis Inc. (NYSE:ZTS) by 30.2% in the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 60,290 shares of the company’s stock after selling 26,124 shares during the period. Pittenger & Anderson Inc.’s holdings in Zoetis were worth $7,586,000 as of its most recent SEC filing.

A number of other institutional investors also recently made changes to their positions in ZTS. CIBC Asset Management Inc grew its position in Zoetis by 4.3% in the third quarter. CIBC Asset Management Inc now owns 251,495 shares of the company’s stock valued at $36,745,000 after acquiring an additional 10,434 shares during the period. Nordea Investment Management AB grew its holdings in shares of Zoetis by 79.2% during the fourth quarter. Nordea Investment Management AB now owns 4,932,787 shares of the company’s stock worth $622,222,000 after purchasing an additional 2,179,578 shares during the last quarter. Seilern Investment Management Ltd grew its holdings in shares of Zoetis by 361.2% during the fourth quarter. Seilern Investment Management Ltd now owns 333,465 shares of the company’s stock worth $41,957,000 after purchasing an additional 261,155 shares during the last quarter. Assenagon Asset Management S.A. grew its holdings in shares of Zoetis by 134.4% during the fourth quarter. Assenagon Asset Management S.A. now owns 1,631,619 shares of the company’s stock worth $205,290,000 after purchasing an additional 935,432 shares during the last quarter. Finally, Mitsubishi UFJ Trust & Banking Corp grew its holdings in shares of Zoetis by 6.5% during the third quarter. Mitsubishi UFJ Trust & Banking Corp now owns 295,482 shares of the company’s stock worth $43,235,000 after purchasing an additional 18,040 shares during the last quarter. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Zoetis Trading Down 0.7%

NYSE:ZTS opened at $114.22 on Friday. Zoetis Inc. has a 1-year low of $112.97 and a 1-year high of $172.23. The business’s 50-day moving average price is $119.93 and its two-hundred day moving average price is $124.67. The company has a current ratio of 3.03, a quick ratio of 1.94 and a debt-to-equity ratio of 2.71. The firm has a market capitalization of $48.05 billion, a price-to-earnings ratio of 18.97, a PEG ratio of 1.76 and a beta of 0.87.

Zoetis (NYSE:ZTS) last released its earnings results on Thursday, February 12th. The company reported $1.48 earnings per share for the quarter, beating the consensus estimate of $1.40 by $0.08. Zoetis had a return on equity of 62.02% and a net margin of 28.24%.The firm had revenue of $2.39 billion for the quarter, compared to analyst estimates of $2.36 billion. During the same quarter in the prior year, the firm posted $1.40 earnings per share. The company’s quarterly revenue was up 3.0% on a year-over-year basis. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. On average, equities analysts expect that Zoetis Inc. will post 7.01 earnings per share for the current year.

Zoetis Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 2nd. Investors of record on Monday, April 20th will be issued a dividend of $0.53 per share. The ex-dividend date is Monday, April 20th. This represents a $2.12 dividend on an annualized basis and a dividend yield of 1.9%. Zoetis’s dividend payout ratio (DPR) is presently 35.22%.

Wall Street Analyst Weigh In

Several analysts have recently commented on the company. Piper Sandler restated a “neutral” rating and set a $135.00 target price (down from $190.00) on shares of Zoetis in a report on Thursday, January 22nd. Wall Street Zen cut Zoetis from a “buy” rating to a “hold” rating in a report on Saturday. Leerink Partners restated a “market perform” rating on shares of Zoetis in a report on Tuesday, March 10th. Weiss Ratings cut Zoetis from a “hold (c-)” rating to a “sell (d+)” rating in a report on Friday, March 27th. Finally, UBS Group decreased their target price on Zoetis from $136.00 to $130.00 and set a “neutral” rating on the stock in a report on Tuesday, April 28th. Seven investment analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Zoetis has a consensus rating of “Hold” and a consensus target price of $151.75.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.